Martin Čulen

Martin Čulen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
MČMartin Čulen
Martin Čulen
ARAnna Rezacova
Anna Rezacova
Josef JampilekJosef Jampilek
Josef Jampilek
JDJiri Dohnal
Jiri Dohnal

18 July 2022 in American Journal of Hematology
Verified
Journal Article
Open access
BPBarbar Peter
Barbar Peter
GEGregor Eisenwort
Gregor Eisenwort
ISIrina Sadovnik
Irina Sadovnik
KBKarin Bauer
Karin Bauer
MWMichael Willmann
Michael Willmann
Peter ValentPeter Valent
Peter Valent
In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream‐effector MYC as growth regulators and therapeutic targets in CML cells. BRD4 and MYC were found to be expressed in primary CML cells, CD34+/CD38− leukemic stem cells (LSC), and in the CML cell lines KU812, K562, KCL22, and KCL22T315I. The BRD4‐targeting drug JQ1 was found to suppress proliferation in KU812 cells and primary leukemic cells in the majority of patients with chronic phase CML. In the blast phase of CML, JQ1 was less effective. However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. Moreover, dBET6 was found to block MYC expression and to synergize with BCR::ABL1 TKI in inhibiting the proliferation in the JQ1‐resistant cell line K562. Furthermore, BRD4 degradation was found to overcome osteoblast‐induced TKI resistance of CML LSC in a co‐culture system and to block interferon‐gamma‐induced upregulation of the checkpoint antigen PD‐L1 in LSC. Finally, dBET6 was found to suppress the in vitro survival of CML LSC and their engraftment in NSG mice. Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC.

10 December 2019 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ZHZdenka Herudkova
Zdenka Herudkova
MČMartin Čulen
Martin Čulen
AFAdam Folta
Adam Folta
IJIvana Jeziskova
Ivana Jeziskova
JCJana Cerna
Jana Cerna
ZRZdenek Racil
Zdenek Racil

2 May 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MČMartin Čulen
Martin Čulen
ZKZdenka Kosarova
Zdenka Kosarova
IJIvana Jeziskova
Ivana Jeziskova
AFAdam Folta
Adam Folta
JCJana Chovancova
Jana Chovancova
ZRZdenek Racil
Zdenek Racil

23 November 2017 in Molecules
Verified
Journal Article
Open access
PDF file
ISIvan Stupák
Ivan Stupák
SPSylvie Pavloková
Sylvie Pavloková
Jakub VysloužilJakub Vysloužil
Jakub Vysloužil
JDJiří Dohnal
Jiří Dohnal
MČMartin Čulen
Martin Čulen
Biorelevant dissolution instruments represent an important tool for pharmaceutical research and development. These instruments are designed to simulate the dissolution of drug formulations in conditions most closely mimicking the gastrointestinal tract. In this work, we focused on the optimization of dissolution compartments/vessels for an updated version of the biorelevant dissolution apparatus—Golem v2. We designed eight compartments of uniform size but different inner geometry. The dissolution performance of the compartments was tested using immediate release caffeine tablets and evaluated by standard statistical methods and principal component analysis. Based on two phases of dissolution testing (using 250 and 100 mL of dissolution medium), we selected two compartment types yielding the highest measurement reproducibility. We also confirmed a statistically ssignificant effect of agitation rate and dissolution volume on the extent of drug dissolved and measurement reproducibility.

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MČMartin Čulen
Martin Čulen
PTPaweł K. Tuszyński
Paweł K. Tuszyński
SPSebastian Polak
Sebastian Polak
RJRenata Jachowicz
Renata Jachowicz
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
JDJiří Dohnal
Jiří Dohnal
Different batches of atorvastatin, represented by two immediate release formulation designs, were studied using a novel dynamic dissolution apparatus, simulating stomach and small intestine. A universal dissolution method was employed which simulated the physiology of human gastrointestinal tract, including the precise chyme transit behavior and biorelevant conditions. The multicompartmental dissolution data allowed direct observation and qualitative discrimination of the differences resulting from highly pH dependent dissolution behavior of the tested batches. Further evaluation of results was performed using IVIVC/IVIVR development. While satisfactory correlation could not be achieved using a conventional deconvolution based-model, promising results were obtained through the use of a nonconventional approach exploiting the complex compartmental dissolution data.